Internal Medicine, Hematology & Oncology · Plantation, FL
NPI
1679807242
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
8200 W Sunrise Blvd Bldg C
Plantation, FL, 33322
Phone (954) 370-8585
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.4M
149,017 services
Medicare patients, 2024
455
Average age 75
Drug cost, 2024
$9.6M
3,184 prescriptions
Company payments, 2025
$4,718
From 48 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harshad V Amin was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 30,240 times for 40 patients. In total Harshad V Amin billed 149,017 services in 106 codes, and Medicare paid $3.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-04-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 30,240 | 40 | $2.32 | $70K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,200 | 15 | $44.91 | $728K |
| J0897 Injection, denosumab, 1 mg | Office | 5,760 | 27 | $20.42 | $118K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,900 | 30 | $15.67 | $61K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,377 | 48 | $0.09 | $124 |
| 85025 Blood Count | Office | 1,339 | 364 | $7.59 | $10K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 654 | 18 | $0.23 | $148 |
| 99212 Office E&M - Established | Office | 557 | 205 | $49.00 | $27K |
| 99213 Office E&M - Established | Office | 376 | 215 | $70.77 | $27K |
| 96367 Intravenous Infusion, Hydration | Office | 278 | 57 | $23.96 | $6,660 |
| 96372 Injection Administration | Office | 273 | 82 | $11.74 | $3,204 |
| 96413 Chemotherapy Administration | Office | 252 | 45 | $108.70 | $27K |
| 99214 Office E&M - Established | Office | 163 | 123 | $81.42 | $13K |
| 99233 Hospital E&M - Subsequent | Facility | 115 | 44 | $99.86 | $11K |
| 96401 Chemotherapy Administration | Office | 110 | 14 | $60.51 | $6,656 |
By year: 2022 $1.9M for 144,726 services; 2023 $2.7M for 156,684 services; 2024 $3.4M for 149,017 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,339 | 364 | $7.59 | $10K |
| 36415 Venipuncture Blood Collection | 32 | 18 | $8.65 | $277 |
Medicare prescription drug claims, 2024
In 2024, the drug Harshad V Amin prescribed most often to Medicare patients was Letrozole, with 244 prescriptions and refills. In total Harshad V Amin wrote 3,184 Medicare prescriptions that cost $9.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 244 | 662 | 81 | $4,617 |
| Prednisone Generic | 183 | 210 | 55 | $920 |
| Eliquis Apixaban | 178 | 254 | 42 | $145K |
| Montelukast Sodium Generic | 121 | 208 | 48 | $592 |
| Sodium Chloride 0.9 % Sodium Chloride | 95 | 95 | Under 11 | $417 |
| Hydroxyurea Generic | 95 | 205 | 28 | $3,015 |
| Abiraterone Acetate Generic | 94 | 94 | 12 | $266K |
| Megestrol Acetate Generic | 92 | 157 | 51 | $3,377 |
| Anastrozole Generic | 91 | 236 | 31 | $1,479 |
| Lenalidomide Generic | 90 | 90 | 13 | $1.3M |
| Dexamethasone Generic | 86 | 124 | 50 | $2,540 |
| Ondansetron Hcl Generic | 73 | 73 | 37 | $648 |
| Gabapentin Generic | 73 | 76 | 30 | $529 |
| Xarelto Rivaroxaban | 60 | 110 | 18 | $59K |
| Pomalyst Pomalidomide | 59 | 59 | Under 11 | $1.4M |
Brand drugs: 880 claims; generic drugs: 2,304 claims; opioid claims: 117.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harshad V Amin $4,718 ($4,718 in general payments such as food, travel and fees) from 48 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $603.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 23 | $603 |
| Pfizer Inc. PFE | 41 | $555 |
| Merck Sharp & Dohme LLC MRK | 15 | $396 |
| Genentech USA, Inc. ROG.SW | 14 | $236 |
| E.R. Squibb & Sons, L.L.C. BMY | 22 | $219 |
| Abbvie Inc. ABBV | 8 | $201 |
| Genzyme Corporation SNY | 7 | $182 |
| Incyte Corporation INCY | 7 | $157 |
| Array Biopharma Inc PFE | 6 | $144 |
| Rigel Pharmaceuticals, Inc. RIGL | 7 | $137 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.